← Leaderboards
Shiladitya Sengupta
Brigham And Women'S Hospital
$10,066,982
Attributed
$14,242,613
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,242,613 · 7
By mechanism
R01$10,304,903 · 5
U01$3,540,991 · 1
R21$396,719 · 1
Top collaborators
- Hae Lin Jang8 shared
- Ali Khademhosseini5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Toshimichi Shinohara$2,619,875
- Shruti Gupta$1,120,717
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMalignant NeoplasmsPharmaceutical PreparationsIn VitroTumorEngineeringCellsEfficacy TestingToxic EffectExhibitsInsightBaseCancer CellResponseBiomedical EngineeringNanoparticleComplexQuality Of LifeImmunotherapyPhenotype3-DimensionalNanotechnologyMetabolicStructure
Grant awards (27)
Nanostructured degradable bone cement for delivering novel antibiotics$697,516
R01 · FY2025 · EB · contact PI
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells$690,825
R01 · FY2025 · CA · contact PI
Tunneling Nanotube Inhibitors for Cancer Immunotherapy$653,121
R01 · FY2025 · CA · contact PI
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells$690,825
R01 · FY2024 · CA · contact PI
Nanostructured degradable bone cement for delivering novel antibiotics$683,565
R01 · FY2024 · EB · contact PI
Tunneling Nanotube Inhibitors for Cancer Immunotherapy$620,466
R01 · FY2024 · CA · contact PI
Investigating nanotube-mediated mitochondria transfer and inhibitor effects in cancer-immune cell interactions across 2D and 3D models$259,550
R01 · FY2024 · CA · contact PI
Tunneling Nanotube Inhibitors for Cancer Immunotherapy$153,677
R01 · FY2024 · CA · contact PI
Nanostructured degradable bone cement for delivering novel antibiotics$697,795
R01 · FY2023 · EB · contact PI
Tunneling Nanotube Inhibitors for Cancer Immunotherapy$652,634
R01 · FY2023 · CA · contact PI
Whitlockite nanoparticle-based immunotherapy for bone metastasis$531,867
R01 · FY2023 · CA · contact PI
Whitlockite nanoparticle-based immunotherapy for bone metastasis$531,867
R01 · FY2022 · CA · contact PI
Engineering personalized micro-tumor ecosystems$614,945
U01 · FY2021 · CA · contact PI
Whitlockite nanoparticle-based immunotherapy for bone metastasis$542,721
R01 · FY2021 · CA · contact PI
Engineering personalized micro-tumor ecosystems$742,092
U01 · FY2020 · CA · contact PI
Whitlockite nanoparticle-based immunotherapy for bone metastasis$551,431
R01 · FY2020 · CA · contact PI
Engineering personalized micro-tumor ecosystems$775,492
U01 · FY2019 · CA · contact PI
Whitlockite nanoparticle-based immunotherapy for bone metastasis$573,510
R01 · FY2019 · CA · contact PI
Engineering personalized micro-tumor ecosystems$754,767
U01 · FY2018 · CA · contact PI
Engineering personalized micro-tumor ecosystems$653,695
U01 · FY2017 · CA · contact PI
Engineering a supramolecular platinum nanoparticle for pediatric cancer$181,037
R21 · FY2015 · CA · contact PI
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways$348,498
R01 · FY2014 · CA · contact PI
Engineering a supramolecular platinum nanoparticle for pediatric cancer$215,682
R21 · FY2014 · CA · contact PI
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways$337,720
R01 · FY2013 · CA · contact PI
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways$359,276
R01 · FY2012 · CA · contact PI
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways$358,689
R01 · FY2011 · CA · contact PI
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways$369,350
R01 · FY2010 · CA · contact PI